The new Medicines Australia Code of Conduct will increase transparency about the vital role of healthcare professionals in the development and use of new, innovative medicines. Healthcare professionals help to educate patients about medicines and their safe, ongoing use – a bond of trust that we, as a Medicines Australia member company, want to help make even stronger.
Novartis values the expert knowledge of patient behavior and of management of diseases that comes from interactions with the healthcare community, and from 31 August 2016, Novartis Pharmaceuticals and Alcon, will disclose details of these engagements on this site. Novartis and Alcon Laboratories (Australia) Pty Ltd (a Novartis company) will provide details of reportable payments or transfers of value to a healthcare professional.
Reportable payments or transfers of value are:
Payments for the provision of services such as giving a lecture, chairing an educational meeting, providing advice as a member of an Advisory Board or as a Consultant
Airfares, accommodation and/or conference registration fees to attend medical education as part of those services.
The report are downloadable below, and these will be available for at least 3 years from the date of publication.
Novartis Pharmaceuticals - 1 November 2016 to 30 April 2017 (PDF) (CSV) *Alcon is no longer required to report due to 2016 transfer of the Ophthalmic Pharmaceuticals franchise from the Alcon Division to the Novartis Pharmaceuticals Division
Alcon - 1 May 2016 to 31 October 2016 (PDF) (CSV) Novartis Pharmaceuticals - 1 May 2016 to 31 October 2016 (PDF) (CSV)
Alcon - 1 October 2015 to 30 April 2016 (PDF) (CSV) Novartis Pharmaceuticals - 1 October 2015 to 30 April 2016 (PDF) (CSV)
To comply with our privacy obligations, the report may be amended from time to time. The reports here contains the most up to date information. Any use or disclosure of the data by a third party is the responsibility of that third party, who must comply with the Australian Privacy Act 1988.